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INTRODUCTION
Members of the genus Bartonella are gram-nega-
tive, oxidase-negative, fastidious bacteria belong-
ing to the alpha2 subclass of Proteobacteria [1].
Bartonella quintana is transmitted by the human
body louse, and humans are the only known
reservoir [1]. An acute form (trench fever) and a
chronic form (chronic bacteraemia) of the disease
have been reported in immunocompetent individ-
uals [1]. Trench fever, also known as 5-day fever or
quintan fever, is a manifestation of initial infection
with B. quintana and is characterised by infection
of human red blood cells [2]. Of the Bartonella
species, B. quintana is the one that most commonly
causes endocarditis, followed by B. henselae [3].
The ﬁrst case of Bartonella endocarditis was
reported in an HIV-infected homosexual man in
1993. B. quintana endocarditis has subsequently
been reported in three non-HIV infected, homeless
men in France [1]. B. quintana endocarditis is most
often observed in homeless people with chronic
alcoholism and exposure to body lice and in
patients without previously known valvulopathy
[3]. Currently recommended antibiotics for the
treatment of B. quintana infections are doxycycline
in combination with gentamicin [4]. The aim of
this study was to assess in vitro the antibiotic
resistance of B. quintana against doxycycline,
amoxicillin and rifampin and the potential mech-
anism of antibiotic resistance by molecular study.
MATERIALS AND METHODS
The Bartonella quintana strain Oklahoma was grown on
Columbia 5% sheep blood agar plates. Selection of antibiotic-
resistant mutants was performed by serial passages of
B. quintana in blood agar plate containing a disk of antibiotic
(rifampin, amoxicillin and doxycycline) (Mast Diagnostics,
Amiens, France) initially placed in the corner or in the centre of
the plate according to the measurement of diameter of growth
inhibition as previously described [5]. The plates were incu-
bated at 37C and diameters of growth inhibition (in mm) were
measured every 2 weeks. The conﬂuent growth outside the
zone of inhibition was harvested with an inoculation loop and
subcultured every 2 weeks until the strain became completely
resistant. The antibiotic-susceptible strain and the antibiotic-
resistant mutants were screened for the molecular support of
antibiotic resistance by PCR ampliﬁcation and DNA sequenc-
ing analysis. Speciﬁc oligonucleotidic primers for the candi-
date genes were designed according to the complete genome
sequences of Bartonella species available at the KEGG website
(http://www.genome.jp) [5]. The nucleotide sequences of the
candidate genes were compared and aligned to look at
possible mutations known to be associated with antibiotic
resistance using the CLUSTALW program.
RESULTS
In-vitro selection of B. quintana with doxycycline
and amoxicillin was unsuccessful even after 24
and 10 passages, respectively. A rifampin-resis-
tant mutant was obtained after three subcultures
of the parental strain on blood agar plates after
the third passage (Fig. 1a), with the strain grow-
ing directly in contact with the disk. Partial
sequence of the rifampin-resistance determining
region (RRDR) of the rpoB gene revealed that the
rifampin-resistant strain of B. quintana harboured
an amino acid change at position 531 (Ser to Phe),
Escherichia coli numbering (Fig. 1b).
DISCUSSION
For the ﬁrst time, in this study, we have selected
in vitro a rifampin-resistant strain of B. quintana
by serial passages of the parental strain on blood
agar plate containing a disk of rifampin. Resis-
tance to rifampicin is almost exclusively associ-
ated with mutations in the rpoB gene encoding
the RNA polymerase ß-subunit (Fig. 1c). In the
great majority of the rifampicin-resistant isolates,
mutations occurred within an 81 bp hotspot
region (the rifampicin resistance-determining
region (RRDR), encoding 27 amino acids and
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corresponding to codons 507–533 or cluster I
according to E. coli numbering) in the centre of
the 3516 bp rpoB gene [5]. Resistance to rifampin
can also be due to an efﬂux system. In our study,
we found that the rifampin-resistant strain of B.
quintana had an amino acid change at position
531 (Ser to Phe) in the rifampin resistance
determining region (RRDR) of the rpoB gene.
Interestingly, we have recently reported the same
mutation obtained also after three passages with
rifampin for B. bacilliformis, the causative agent of
Carrion’s disease [5]. This study also conﬁrms
the high level of in-vitro susceptibility of B. quin-
tana to doxycycline and amoxicillin even after a
long time of in-vitro selection. Thus, it seems
reasonable to prefer doxycycline in association
with another antibiotic for the treatment of
patients with B. quintana infections (bacteraemia
in homeless people or endocarditis). On the other
hand, as it is very easy to obtain the rifampin-
resistant strain of B. quintana in vitro, we believe
that this compound should not be used alone in
the treatment of human bartonellosis.
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Fig. 1. Kinetic of decrease of the diameter of growth
inhibition around the disk of rifampin during the selection
of the mutant strain of B. quintana Oklahoma cultured on
blood agar plates (a), and amino acid (AA) sequences
(E. coli numbering) of Rifampin-susceptible (RifS) and
rifampin-resistant (RifR) strains of B. Quintana showing the
Ser531Phe mutation (b). Structure of RNA polymerase
showing the b subunit, the binding site of the antibiotic
rifampin (c).
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